eClinical Research

Clinical Innovation

After Approval, Into the Void: The Systemic Failure of Postmarket Drug Safety Monitoring

FDA approval is widely understood as a threshold of safety, yet the surveillance infrastructure designed to monitor drugs once they reach patients is riddled with structural deficiencies that allow adverse events to accumulate undetected for years. This investigation examines the regulatory gaps, financial disincentives, and institutional inertia that collectively undermine postmarket pharmacovigilance in the United States. The consequences, as several high-profile cases illustrate, extend far b

Sep 20, 2026

Research Methodology

The Unmined Record: Why Frontline Clinical Observations Fail to Reach the Evidence Base

Across American health systems, electronic health records accumulate billions of clinical observations annually—pattern recognitions, treatment responses, diagnostic pivots, and outcome variations that never travel beyond the institution where they were recorded. This article examines the structural, cultural, and logistical barriers that prevent practicing clinicians from converting real-world observations into publishable evidence, and considers what the medical community loses when that knowl

Sep 20, 2026

Research Methodology

Invisible Evidence: How Unpublished Negative Trial Data Is Quietly Shaping Clinical Decisions

Thousands of clinical trials that produced null or unfavorable results have never entered the published record, leaving physicians to prescribe and policy makers to recommend based on a curated — and therefore distorted — body of evidence. This investigation examines the structural forces sustaining publication bias, highlights recent cases where suppressed negative data contradicted established treatment protocols, and evaluates whether emerging regulatory mandates and open-science technologies

Sep 20, 2026

Clinical Innovation

Last-Mile Medicine: The Structural Barriers Preventing Clinical Breakthroughs From Reaching Underserved Americans

Landmark clinical discoveries validated in controlled trial settings routinely fail to translate into improved outcomes for patients in underserved communities, exposing a profound and underexamined gap between scientific progress and equitable care delivery. This analysis examines the infrastructure deficits, financial constraints, and systemic access barriers that concentrate the benefits of clinical innovation among already-advantaged populations, and surveys the policy and implementation str

Sep 20, 2026

Research Methodology

Buried Data, Broken Trust: The Hidden Crisis of Selective Outcome Reporting in Clinical Research

When researchers and trial sponsors publish only the outcomes that favor their hypotheses, the cumulative body of medical evidence becomes systematically distorted. This investigation examines the structural incentives driving selective reporting, documents cases where outcome switching enabled the widespread adoption of ineffective therapies, and evaluates emerging technological frameworks designed to enforce accountability across the research pipeline.

Sep 19, 2026

Clinical Innovation

The Representation Gap: How Racially Homogeneous Clinical Trials Are Undermining Care for Millions of Americans

Decades of clinical research conducted predominantly in white patient populations have produced an evidence base that frequently fails to account for the biological, pharmacological, and social heterogeneity of the United States' diverse patient population. This analysis documents the treatment harms that have emerged from this gap, examines the systemic barriers preventing equitable trial enrollment, and profiles the institutional reforms and policy interventions working to build a more inclusi

Sep 19, 2026

Research Methodology

Unregistered, Unreported, Unaccountable: The Systemic Collapse of Clinical Trial Transparency

Incomplete trial registration, selective outcome reporting, and chronic delays in data disclosure continue to erode the credibility of clinical research in the United States. Despite regulatory frameworks designed to enforce transparency, compliance gaps persist across academic medical centers, industry sponsors, and federal agencies alike. This analysis examines where the system is failing—and which institutions are pioneering meaningful reform.

Sep 19, 2026

Clinical Innovation

Algorithms in the Protocol Room: Assessing AI's Genuine Impact on Clinical Trial Design

Machine learning and artificial intelligence are increasingly embedded in the architecture of clinical trials, from patient recruitment algorithms to real-time safety monitoring systems. Yet enthusiasm for these tools frequently outpaces the evidence supporting their reliability, and regulatory frameworks have struggled to keep pace with rapid deployment. This analysis weighs documented gains against underappreciated risks—and asks what rigorous validation of AI in clinical research would actual

Sep 19, 2026

Clinical Innovation

Beyond the Randomized Trial: How Real-World Evidence Is Redefining Clinical Practice in 2024

Real-world evidence derived from electronic health records, claims databases, and patient registries is increasingly informing clinical decision-making and regulatory policy across US healthcare institutions. As the FDA and CMS accelerate frameworks for integrating observational data alongside traditional trial findings, precision medicine and population health strategies stand to be fundamentally transformed.

Sep 19, 2026

Research Methodology

Shaky Foundations: Confronting the Replication Failures Threatening the Integrity of US Clinical Research

A growing body of evidence suggests that a substantial proportion of peer-reviewed clinical trial findings cannot be reliably reproduced, exposing systemic vulnerabilities in study design, reporting practices, and institutional incentives. This analysis examines the structural causes of the reproducibility crisis and outlines evidence-based strategies for strengthening the scientific foundation of clinical medicine in the United States.

Sep 19, 2026